Abbott Laboratories Gets Expanded Indication for Infinity Deep Brain Stimulation System
January 24 2020 - 9:44AM
Dow Jones News
By Michael Dabaie
Abbott Laboratories (ABT) said it received approval from the
U.S. Food and Drug Administration for a new, expanded indication
for the company's Infinity Deep Brain Stimulation system.
The company said the indication was expanded to include
targeting of an area of the brain called the internal globus
pallidus, or GPi. The GPi plays an integral role in the motor
function and can be targeted with DBS to improve the symptoms of
Parkinson's disease not adequately controlled by medication, the
company said.
Abbott shares were up 1.4% in light premarket trading to
$92.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
January 24, 2020 09:29 ET (14:29 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
From Apr 2023 to Apr 2024
